US OptionsDetailed Quotes
AVXL241115C12000
- 0.00
- 0.000.00%
15min DelayClose Nov 6 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest12.00Strike Price0.00Turnover0.00%IV54.04%PremiumNov 15, 2024Expiry Date0.00Intrinsic Value100Multiplier9DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma77.90Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Anavex Life Sciences Stock Discussion
Sign in to post a comment
$Anavex Life Sciences (AVXL.US)$ Hello 8. been expecting you. let's see if this can hold, if it can then I think it's possible to see the next step at 8.15 to 8.25
4
$Anavex Life Sciences (AVXL.US)$ well, looks there. possible to reach 8.0 next
$Anavex Life Sciences (AVXL.US)$ This is riding the upper band on Bollinger day, hour and 15 min charts, I think it's possible to see 7.50 to 7.60 soon.
2
$Roblox (RBLX.US)$ $Anavex Life Sciences (AVXL.US)$ $Santech Holdings (STEC.US)$ $Lead Real Estate (LRE.US)$ $Avadel Pharmaceuticals (AVDL.US)$ $Carvana (CVNA.US)$ $Lemonade (LMND.US)$ $Autonomix Medical (AMIX.US)$ $Peloton Interactive (PTON.US)$ $PLBY Group (PLBY.US)$ $Alphatec (ATEC.US)$ $Universal Security Instruments (UUU.US)$ $Biofrontera (BFRI.US)$ $Root Inc (ROOT.US)$
🎃⚡️🎃
🎃⚡️🎃
5
3
$Anavex Life Sciences (AVXL.US)$ well, smashed my tp, next tp is 7.30+
$Anavex Life Sciences (AVXL.US)$ This looks to be filling the upper gap on the Bollinger hour chart, I think it possible to see 6.65 to 6.85 again today.
1
$Anavex Life Sciences (AVXL.US)$
Anavex’s Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer’s Trial: Data Presented at CTAD Conference 2024
Anavex Life Sciences presented new data from their Phase IIb/III study of blarcamesine (ANAVEX®2-73) for early Alzheimer's disease at the CTAD Conference 2024. The oral, once-daily treatment demonstrated significant clinical efficacy through SIGMAR1 activation, slowing clinical progression by 36.3% in the primary endpoint ADAS-Cog13...
Anavex’s Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer’s Trial: Data Presented at CTAD Conference 2024
Anavex Life Sciences presented new data from their Phase IIb/III study of blarcamesine (ANAVEX®2-73) for early Alzheimer's disease at the CTAD Conference 2024. The oral, once-daily treatment demonstrated significant clinical efficacy through SIGMAR1 activation, slowing clinical progression by 36.3% in the primary endpoint ADAS-Cog13...
1
$Anavex Life Sciences (AVXL.US)$ This looks like it has crossed the mid band on Bollinger day chart, if it continues possible to see 5.65 to 5.78 soon.
2
No comment yet
Rhiox OP : with this news and the uptrend this is on, I expected this to keep an upward trend. I think it will see 8.10 to 820 today and around 8. 35 by eow